Towards Healthcare
AAV Manufacturing Service Market Trends and Companies

AAV Manufacturing Service Market Expands with Gene Therapy

The critical importance of adeno-associated virus for gene therapies drives the need for its production processes. North America dominated the market in 2024, led by the expanding clinical workflows, increasing research on rare diseases, and major companies in the market.

Content

  • Last Updated: 20 October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The AAV manufacturing service market is projected to grow rapidly, fueled by investments, innovation, and increasing demand across industries by 2034

North America is currently leading the AAV manufacturing service market share by 40% due to a supportive regulatory environment, FDA approvals, and strong regulatory bodies.

Some key players include Oxford Biomedica, Paragon Bioservices, GenScript Biotech, MeiraGTx, Astellas Gene Therapy, Sarepta Therapeutics, BioVectra, Lonza Group, and Catalent Inc.

Key trends include advancements in vector engineering, improved raw materials, analytics, expansion of suspension culture systems, AI integration, growth of CDMO, etc.

NIH, NSF, BARDA, FDA. 
Any Questions